» Articles » PMID: 27144339

FRA1 Promotes Squamous Cell Carcinoma Growth and Metastasis Through Distinct AKT and C-Jun Dependent Mechanisms

Overview
Journal Oncotarget
Specialty Oncology
Date 2016 May 5
PMID 27144339
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

FRA1 (Fos-like antigen 1) is highly expressed in many epithelial cancers including squamous cell carcinoma of the skin (cSCC) and head and neck (HNSCC). However, the functional importance and the mechanisms mediating FRA1 function in these cancers are not fully understood. Here, we demonstrate that FRA1 gene silencing in HNSCC and cSCC cells resulted in two consequences - impaired cell proliferation and migration. FRA1 regulation of cell growth was distinct from that of c-Jun, a prominent Jun group AP-1 factor. While c-Jun was required for the expression of the G1/S phase cell cycle promoter CDK4, FRA1 was essential for AKT activation and AKT-dependent expression of CyclinB1, a molecule required for G2-M progression. Exogenous expression of a constitutively active form of AKT rescued cancer cell growth defect caused by FRA1-loss. Additionally, FRA1 knockdown markedly slowed cell adhesion and migration, and conversely expression of an active FRA1 mutant (FRA1DD) expedited these processes in a JNK/c-Jun-dependent manner. Through protein and ChIP-PCR analyses, we identified KIND1, a cytoskeletal regulator of the cell adhesion molecule β1-integrin, as a novel FRA1 transcriptional target. Restoring KIND1 expression rescued migratory defects induced by FRA1 loss. In agreement with these in vitro data, HNSCC cells with FRA1 loss displayed markedly reduced rates of subcutaneous tumor growth and pulmonary metastasis. Together, these results indicate that FRA1 promotes cancer growth through AKT, and enhances cancer cell migration through JNK/c-Jun, pinpointing FRA1 as a key integrator of JNK and AKT signaling pathways and a potential therapeutic target for cSCC and HNSCC.

Citing Articles

Whole Exome Sequencing of Intracranial Epidermoid Cysts Reveals Immune-Associated Mechanistic and Potential Targets.

Kondaboina S, Parrish O, Parada C, Ferreira Jr M Cancers (Basel). 2024; 16(20).

PMID: 39456581 PMC: 11506683. DOI: 10.3390/cancers16203487.


Novel PROTAC probes targeting FOSL1 degradation to eliminate head and neck squamous cell carcinoma cancer stem cells.

Zaman S, Pagare P, Huang B, Rilee G, Ma Z, Zhang Y Bioorg Chem. 2024; 151:107613.

PMID: 39002513 PMC: 11365795. DOI: 10.1016/j.bioorg.2024.107613.


FOSL1's Oncogene Roles in Glioma/Glioma Stem Cells and Tumorigenesis: A Comprehensive Review.

Khedri A, Guo S, Ramar V, Hudson B, Liu M Int J Mol Sci. 2024; 25(10.

PMID: 38791400 PMC: 11121637. DOI: 10.3390/ijms25105362.


FLI1 and FRA1 transcription factors drive the transcriptional regulatory networks characterizing muscle invasive bladder cancer.

Guneri-Sozeri P, Ozden-Yilmaz G, Kisim A, Cakiroglu E, Eray A, Uzuner H Commun Biol. 2023; 6(1):199.

PMID: 36805539 PMC: 9941102. DOI: 10.1038/s42003-023-04561-3.


Co-Treatment of Chloroquine and Trametinib Inhibits Melanoma Cell Proliferation and Decreases Immune Cell Infiltration.

Degan S, May B, Jin Y, Hammoda M, Sun H, Zhang G Front Oncol. 2022; 12:782877.

PMID: 35847840 PMC: 9282877. DOI: 10.3389/fonc.2022.782877.


References
1.
Abate C, Curran T . Encounters with Fos and Jun on the road to AP-1. Semin Cancer Biol. 1990; 1(1):19-26. View

2.
Margadant C, Kreft M, Zambruno G, Sonnenberg A . Kindlin-1 regulates integrin dynamics and adhesion turnover. PLoS One. 2013; 8(6):e65341. PMC: 3679067. DOI: 10.1371/journal.pone.0065341. View

3.
Hwang A, Maity A, McKenna W, Muschel R . Cell cycle-dependent regulation of the cyclin B1 promoter. J Biol Chem. 1995; 270(47):28419-24. DOI: 10.1074/jbc.270.47.28419. View

4.
Gaykalova D, Mambo E, Choudhary A, Houghton J, Buddavarapu K, Sanford T . Novel insight into mutational landscape of head and neck squamous cell carcinoma. PLoS One. 2014; 9(3):e93102. PMC: 3965530. DOI: 10.1371/journal.pone.0093102. View

5.
Vial E, Sahai E, Marshall C . ERK-MAPK signaling coordinately regulates activity of Rac1 and RhoA for tumor cell motility. Cancer Cell. 2003; 4(1):67-79. DOI: 10.1016/s1535-6108(03)00162-4. View